There are several types of GLP medications that engage different types of glucagon receptors, giving them different effects in different people: Single receptor agonists (GLP-1 only): Ozempic, Wegovy, Saxenda Dual receptor agonists (GLP-1 + GIP): Mounjaro, Zepbound Triple receptor agonists (GLP-1 + GIP + glucagon): in development early studies show even greater metabolic effects These medications are changing how we are able to ameliorate obesity, food addiction, insulin resistance, and cardiometabolic risks
Tissue loading may occur at even lower rates of administration
Because neither compound is licensed in the UK, no formal pharmacokinetic or pharmacodynamic interaction studies have been conducted or reviewed by the MHRA
Protecting Muscle Is Non-Negotiable Heres what too few clinicians are talking about: GLP-1s, by reducing appetite, can unintentionally reduce protein intake , putting your muscle mass at risk
Figure 3 Neuroplasticity Effect The adult brain can adapt to internal and external stressors through structural plasticity, and failed resilience is likely to cause depression and anxiety